Quantify any protein, in any sample, with any modification, without antibodies
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
March 10-14, 2024 Salt Lake City, UT Booth #917 Join Inotiv scientists at SOT held March 10-14, 2024, at the Salt Palace Convention Center in Salt Lak...
WEST LAFAYETTE, IN - November 27, 2023 -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analyti...
November 8, 2023 Attributes 1156% Revenue Growth to Adding Strategic Capacity, Key Integration Initiatives, Optimization of Infrastructure, and Right-Sizing its Global Footprint...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
In Vivo Services
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
